{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:58:07Z","timestamp":1790366287810,"version":"4.1.0"},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2015,10,7]],"date-time":"2015-10-07T00:00:00Z","timestamp":1444176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0139684","type":"journal-article","created":{"date-parts":[[2015,10,7]],"date-time":"2015-10-07T21:23:45Z","timestamp":1444253025000},"page":"e0139684","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":65,"title":["Interleukin-1 Antagonist Anakinra in Amyotrophic Lateral Sclerosis\u2014A Pilot Study"],"prefix":"10.1371","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct01277315","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Andr\u00e9","family":"Maier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaus","family":"Deigendesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen H.","family":"Weishaupt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Krannich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"R\u00f6hle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Meissner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaaweh","family":"Molawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"M\u00fcnch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Holm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Zychlinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,10,7]]},"reference":[{"issue":"9769","key":"ref1","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/S0140-6736(10)61156-7","article-title":"Amyotrophic lateral sclerosis","volume":"377","author":"MC Kiernan","year":"2011","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001447.pub3","article-title":"Riluzole for amyotrophic lateral sclerosis (ALS)\/motor neuron disease (MND)","volume":"3","author":"RG Miller","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"ref3","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJM199403033300901","article-title":"A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS\/Riluzole Study Group","volume":"330","author":"G Bensimon","year":"1994","journal-title":"N Engl J Med"},{"issue":"8","key":"ref4","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1093\/jnen\/63.8.831","article-title":"Glial proliferation and metabotropic glutamate receptor expression in amyotrophic lateral sclerosis","volume":"63","author":"JM Anneser","year":"2004","journal-title":"J Neuropathol Exp Neurol"},{"issue":"4","key":"ref5","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/mus.10191","article-title":"Inflammatory processes in amyotrophic lateral sclerosis","volume":"26","author":"PL McGeer","year":"2002","journal-title":"Muscle Nerve"},{"issue":"3","key":"ref6","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S1474-4422(11)70015-1","article-title":"Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease","volume":"10","author":"T Philips","year":"2011","journal-title":"Lancet Neurol"},{"issue":"3","key":"ref7","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.nbd.2003.12.012","article-title":"Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study","volume":"15","author":"MR Turner","year":"2004","journal-title":"Neurobiol Dis"},{"issue":"1","key":"ref8","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1212\/01.wnl.0000333251.36681.a5","article-title":"A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis","volume":"72","author":"RM Mitchell","year":"2009","journal-title":"Neurology"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1146\/annurev.immunol.021908.132715","article-title":"The inflammasomes: guardians of the body","volume":"27","author":"F Martinon","year":"2009","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"ref10","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1034\/j.1600-0404.2001.103004255.x","article-title":"Interleukin-1beta converting enzyme\/Caspase\u20131 (ICE\/Caspase\u20131) and soluble APO\u20131\/Fas\/CD 95 receptor in amyotrophic lateral sclerosis patients","volume":"103","author":"J Ilzecka","year":"2001","journal-title":"Acta Neurol Scand"},{"issue":"5464","key":"ref11","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1126\/science.288.5464.335","article-title":"Functional role of caspase\u20131 and caspase\u20133 in an ALS transgenic mouse model","volume":"288","author":"M Li","year":"2000","journal-title":"Science"},{"issue":"29","key":"ref12","doi-asserted-by":"crossref","first-page":"13046","DOI":"10.1073\/pnas.1002396107","article-title":"Mutant superoxide dismutase 1-induced IL-1beta accelerates ALS pathogenesis","volume":"107","author":"F Meissner","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"ref13","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrd3800","article-title":"Treating inflammation by blocking interleukin\u20131 in a broad spectrum of diseases","volume":"11","author":"CA Dinarello","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"ref14","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/sj.jcbfm.9600537","article-title":"Interleukin\u20131 receptor antagonist penetrates human brain at experimentally therapeutic concentrations","volume":"28","author":"SR Clark","year":"2008","journal-title":"J Cereb Blood Flow Metab"},{"issue":"2","key":"ref15","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/jcbfm.2010.103","article-title":"Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging study","volume":"31","author":"J Galea","year":"2011","journal-title":"J Cereb Blood Flow Metab"},{"issue":"10","key":"ref16","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1136\/jnnp.2004.054882","article-title":"A randomised phase II study of interleukin\u20131 receptor antagonist in acute stroke patients","volume":"76","author":"HC Emsley","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"49","key":"ref17","doi-asserted-by":"crossref","first-page":"20960","DOI":"10.1073\/pnas.0911405106","article-title":"Activation of innate and humoral immunity in the peripheral nervous system of ALS transgenic mice","volume":"106","author":"IM Chiu","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"ref18","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1212\/WNL.0b013e318249f776","article-title":"Peripheral nerve inflammation in ALS mice: cause or consequence","volume":"78","author":"O Kano","year":"2012","journal-title":"Neurology"},{"issue":"2","key":"ref19","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1179\/174313208X281235","article-title":"Local expression of mIgf\u20131 modulates ubiquitin, caspase and CDK5 expression in skeletal muscle of an ALS mouse model","volume":"30","author":"G Dobrowolny","year":"2008","journal-title":"Neurol Res"},{"issue":"11","key":"ref20","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1093\/hmg\/ddq106","article-title":"Skeletal muscle-restricted expression of human SOD1 causes motor neuron degeneration in transgenic mice","volume":"19","author":"M Wong","year":"2010","journal-title":"Hum Mol Genet"},{"key":"ref21","first-page":"96","article-title":"El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases\/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors","volume":"124","author":"BR Brooks","year":"1994","journal-title":"J Neurol Sci"},{"issue":"5","key":"ref22","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.neurobiolaging.2013.11.034","article-title":"Polymerase chain reaction and Southern blot-based analysis of the C9orf72 hexanucleotide repeat in different motor neuron diseases","volume":"35","author":"A Hubers","year":"2014","journal-title":"Neurobiol Aging"},{"issue":"1\u20132","key":"ref23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0022-510X(99)00210-5","article-title":"The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III)","volume":"169","author":"JM Cedarbaum","year":"1999","journal-title":"J Neurol Sci"},{"issue":"2","key":"ref24","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3109\/17482968.2011.633268","article-title":"Online assessment of ALS functional rating scale compares well to in-clinic evaluation: a prospective trial","volume":"13","author":"A Maier","year":"2012","journal-title":"Amyotroph Lateral Scler"},{"key":"ref25","article-title":"Statistical Methods for Comparative Studies: Techniques for Bias Reduction","author":"S. R. Anderson","year":"2009"},{"issue":"5","key":"ref26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1053\/sarh.2001.23701","article-title":"The safety and efficacy of interleukin\u20131 receptor antagonist in the treatment of rheumatoid arthritis","volume":"30","author":"B Bresnihan","year":"2001","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"ref27","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S1474-4422(13)70036-X","article-title":"Controversies and priorities in amyotrophic lateral sclerosis","volume":"12","author":"MR Turner","year":"2013","journal-title":"Lancet Neurol"},{"issue":"6","key":"ref28","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1600-0404.2008.01112.x","article-title":"Low-grade systemic inflammation in patients with amyotrophic lateral sclerosis","volume":"119","author":"D Keizman","year":"2009","journal-title":"Acta Neurol Scand"},{"issue":"7\u20138","key":"ref29","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1345\/aph.1A396","article-title":"Anakinra treatment of patients with rheumatoid arthritis","volume":"36","author":"LH Calabrese","year":"2002","journal-title":"Ann Pharmacother"},{"issue":"11","key":"ref30","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1111\/j.1468-1331.2008.02307.x","article-title":"Causes of death amongst French patients with amyotrophic lateral sclerosis: a prospective study","volume":"15","author":"J Gil","year":"2008","journal-title":"Eur J Neurol"},{"issue":"1","key":"ref31","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/17482960701656940","article-title":"Causes of death in a post-mortem series of ALS patients","volume":"9","author":"P Corcia","year":"2008","journal-title":"Amyotroph Lateral Scler"},{"issue":"6","key":"ref32","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/ard.2004.033662","article-title":"Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice","volume":"65","author":"AA den Broeder","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"ref33","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/art.10870","article-title":"Anakinra, a recombinant human interleukin\u20131 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial","volume":"48","author":"RM Fleischmann","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"6","key":"ref34","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/ana.10374","article-title":"Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS","volume":"52","author":"DB Drachman","year":"2002","journal-title":"Ann Neurol"},{"issue":"1","key":"ref35","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/ana.20903","article-title":"Trial of celecoxib in amyotrophic lateral sclerosis","volume":"60","author":"ME Cudkowicz","year":"2006","journal-title":"Ann Neurol"},{"issue":"12","key":"ref36","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1474-4422(07)70270-3","article-title":"Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial","volume":"6","author":"PH Gordon","year":"2007","journal-title":"Lancet Neurol"},{"issue":"10","key":"ref37","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1212\/01.WNL.0000125321.92112.7E","article-title":"Placebo-controlled phase I\/II studies of minocycline in amyotrophic lateral sclerosis","volume":"62","author":"PH Gordon","year":"2004","journal-title":"Neurology"},{"issue":"3","key":"ref38","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3109\/21678421.2013.769718","article-title":"ALSUntangled No. 19: Sodium chlorite","volume":"14","year":"2013","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"2","key":"ref39","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1212\/WNL.54.2.469","article-title":"A randomized controlled trial of recombinant interferon beta-1a in ALS. Italian Amyotrophic Lateral Sclerosis Study Group","volume":"54","author":"E Beghi","year":"2000","journal-title":"Neurology"},{"issue":"4","key":"ref40","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00415-008-0756-3","article-title":"Thalidomide causes sinus bradycardia in ALS","volume":"255","author":"T Meyer","year":"2008","journal-title":"J Neurol"},{"issue":"5\u20136","key":"ref41","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3109\/17482960802709416","article-title":"Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: a phase II open label clinical trial","volume":"10","author":"EW Stommel","year":"2009","journal-title":"Amyotroph Lateral Scler"},{"issue":"10","key":"ref42","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s00415-010-5609-1","article-title":"Progression in ALS is not linear but is curvilinear","volume":"257","author":"PH Gordon","year":"2010","journal-title":"J Neurol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0139684","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T13:53:16Z","timestamp":1540216396000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0139684"}},"subtitle":[],"editor":[{"given":"Alfonso","family":"Fasano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,10,7]]},"references-count":42,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2015,10,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0139684","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,7]]}}}